- Zacks•6 hours ago
Minerva Neurosciences, Inc. (NERV) announced the results of additional data analyses from phase IIb clinical trial of MIN-101, as monotherapy in patients with negative symptoms of schizophrenia.
- GlobeNewswire•9 hours ago
FDA Review of Investigational New Drug Application for SNS-062 Complete; Phase 1 B/2 Study in Patients with Advanced B-Cell Malignancies to Begin Dosing in the First Half of 2017. Vosaroxin Day 180 List ...
- Zacks•3 days ago
Aduro Biotech, Inc. (ADRO) announced that it has inked an exclusive license agreement with Stanford University for state-of-the-art neo-antigen identification technology.
SNSS : Summary for Sunesis Pharmaceuticals, Inc. - Yahoo Finance
Sunesis Pharmaceuticals, Inc. (SNSS)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||4.02 x 100|
|Ask||4.04 x 400|
|Day's Range||3.95 - 4.05|
|52 Week Range||2.64 - 6.30|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.37|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|